Linked Life Data

10462249

Source:http://linkedlifedata.com/resource/pubmed/id/10462249

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10462249rdf:typepubmed:Citationlld:pubmed
pubmed-article:10462249lifeskim:mentionsumls-concept:C0014049lld:lifeskim
pubmed-article:10462249lifeskim:mentionsumls-concept:C0019704lld:lifeskim
pubmed-article:10462249lifeskim:mentionsumls-concept:C0033684lld:lifeskim
pubmed-article:10462249lifeskim:mentionsumls-concept:C0042210lld:lifeskim
pubmed-article:10462249lifeskim:mentionsumls-concept:C0184511lld:lifeskim
pubmed-article:10462249lifeskim:mentionsumls-concept:C0679199lld:lifeskim
pubmed-article:10462249lifeskim:mentionsumls-concept:C0086022lld:lifeskim
pubmed-article:10462249lifeskim:mentionsumls-concept:C1707689lld:lifeskim
pubmed-article:10462249lifeskim:mentionsumls-concept:C1705099lld:lifeskim
pubmed-article:10462249lifeskim:mentionsumls-concept:C0442335lld:lifeskim
pubmed-article:10462249pubmed:issue23-24lld:pubmed
pubmed-article:10462249pubmed:dateCreated1999-12-16lld:pubmed
pubmed-article:10462249pubmed:abstractTextA live virus vaccine vector has been constructed from a molecularly cloned attenuated strain of Venezuelan equine encephalitis virus (VEE). High levels of foreign protein expression are regulated by an additional copy of the 26 S viral subgenomic RNA promoter. The position of this additional promoter and foreign gene in the VEE genome was predicted to have a major influence on expression level of the heterologous protein. Two sites in the genome were tested to determine the optimal site for expression of the matrix/capsid (MA/CA) coding region of human immunodeficiency virus (HIV-1). One vector contained the additional promoter and the MA/CA genes immediately downstream of the VEE E1 gene at the 3' end of the genome. In the second vector, the additional promoter was introduced immediately upstream from the authentic 26 S subgenomic promoter. Significantly higher levels of MA/CA were expressed from the downstream vector compared to the upstream vector. However, the stability of expression for both vectors was similar following passage in baby hamster kidney cells (BHK) cells. In BALB/c mice, the two vectors elicited similar levels of cellular immune responses to MA/CA as determined by bulk cytotoxic T-lymphocyte assays and precursor frequency analysis, but the humoral response induced by the downstream vector was significantly stronger. At 11 months post boosting with the downstream vector, serum antibody levels against HIV MA/CA were undiminished, and MA/CA specific CTLp were detectable in all mice tested. These findings suggest that VEE vectors can be optimized to elicit strong, balanced and long-lived immune responses to foreign viral proteins.lld:pubmed
pubmed-article:10462249pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10462249pubmed:languageenglld:pubmed
pubmed-article:10462249pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10462249pubmed:citationSubsetIMlld:pubmed
pubmed-article:10462249pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10462249pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10462249pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10462249pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10462249pubmed:statusMEDLINElld:pubmed
pubmed-article:10462249pubmed:monthAuglld:pubmed
pubmed-article:10462249pubmed:issn0264-410Xlld:pubmed
pubmed-article:10462249pubmed:authorpubmed-author:JohnstonR ERElld:pubmed
pubmed-article:10462249pubmed:authorpubmed-author:SwanstromRRlld:pubmed
pubmed-article:10462249pubmed:authorpubmed-author:FrelingerJ...lld:pubmed
pubmed-article:10462249pubmed:authorpubmed-author:DavisN LNLlld:pubmed
pubmed-article:10462249pubmed:authorpubmed-author:BettsM RMRlld:pubmed
pubmed-article:10462249pubmed:authorpubmed-author:CaleyI JIJlld:pubmed
pubmed-article:10462249pubmed:issnTypePrintlld:pubmed
pubmed-article:10462249pubmed:day6lld:pubmed
pubmed-article:10462249pubmed:volume17lld:pubmed
pubmed-article:10462249pubmed:ownerNLMlld:pubmed
pubmed-article:10462249pubmed:authorsCompleteYlld:pubmed
pubmed-article:10462249pubmed:pagination3124-35lld:pubmed
pubmed-article:10462249pubmed:dateRevised2008-11-21lld:pubmed
pubmed-article:10462249pubmed:meshHeadingpubmed-meshheading:10462249...lld:pubmed
pubmed-article:10462249pubmed:meshHeadingpubmed-meshheading:10462249...lld:pubmed
pubmed-article:10462249pubmed:meshHeadingpubmed-meshheading:10462249...lld:pubmed
pubmed-article:10462249pubmed:meshHeadingpubmed-meshheading:10462249...lld:pubmed
pubmed-article:10462249pubmed:meshHeadingpubmed-meshheading:10462249...lld:pubmed
pubmed-article:10462249pubmed:meshHeadingpubmed-meshheading:10462249...lld:pubmed
pubmed-article:10462249pubmed:meshHeadingpubmed-meshheading:10462249...lld:pubmed
pubmed-article:10462249pubmed:meshHeadingpubmed-meshheading:10462249...lld:pubmed
pubmed-article:10462249pubmed:meshHeadingpubmed-meshheading:10462249...lld:pubmed
pubmed-article:10462249pubmed:meshHeadingpubmed-meshheading:10462249...lld:pubmed
pubmed-article:10462249pubmed:meshHeadingpubmed-meshheading:10462249...lld:pubmed
pubmed-article:10462249pubmed:meshHeadingpubmed-meshheading:10462249...lld:pubmed
pubmed-article:10462249pubmed:meshHeadingpubmed-meshheading:10462249...lld:pubmed
pubmed-article:10462249pubmed:meshHeadingpubmed-meshheading:10462249...lld:pubmed
pubmed-article:10462249pubmed:meshHeadingpubmed-meshheading:10462249...lld:pubmed
pubmed-article:10462249pubmed:meshHeadingpubmed-meshheading:10462249...lld:pubmed
pubmed-article:10462249pubmed:meshHeadingpubmed-meshheading:10462249...lld:pubmed
pubmed-article:10462249pubmed:meshHeadingpubmed-meshheading:10462249...lld:pubmed
pubmed-article:10462249pubmed:meshHeadingpubmed-meshheading:10462249...lld:pubmed
pubmed-article:10462249pubmed:meshHeadingpubmed-meshheading:10462249...lld:pubmed
pubmed-article:10462249pubmed:year1999lld:pubmed
pubmed-article:10462249pubmed:articleTitleVenezuelan equine encephalitis virus vectors expressing HIV-1 proteins: vector design strategies for improved vaccine efficacy.lld:pubmed
pubmed-article:10462249pubmed:affiliationDepartment of Microbiology and Immunology, School of Medicine, University of North Carolina, Chapel Hill 27599, USA.lld:pubmed
pubmed-article:10462249pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10462249pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:10462249pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:10462249pubmed:publicationTypeResearch Support, U.S. Gov't, Non-P.H.S.lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10462249lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10462249lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10462249lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10462249lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10462249lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10462249lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10462249lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10462249lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10462249lld:pubmed